Cite
HARVARD Citation
Scherpereel, A. et al. (2022). First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung cancer. pp. 8-16. [Online].